| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/29/2004 | US20040019077 Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity |
| 01/29/2004 | US20040019072 Dimer-selective RXR modulators and methods for their use |
| 01/29/2004 | US20040019071 Preferential opiate receptors, used as analgesics, antitussive agents, immunosuppressants or neuroprotectants; side effect reduction |
| 01/29/2004 | US20040019070 Nitrogen compounds used as opiate receptor agonists or antagonists, for prophylaxis of drug abuse, cardiovascular, respiratory system, gastrointestinal disorders, as analgesics, antitussives or immunosuppressants |
| 01/29/2004 | US20040019068 Nitrogen compounds such as 2-(5-formylamino-6-oxo-2-phenyl-1,6 -dihydropyrimidin-1-yl)-N-(2,3-dioxo-1-phenylmethyl-6-(2 -pyridyloxy))hexylacetamide used for prophylaxis cardiovascular disorders; restenosis |
| 01/29/2004 | US20040019065 Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use |
| 01/29/2004 | US20040019060 Drugs such as 9-(3,5-dimethyl-1-piperazinyl)propyl)carbazole, used for modulating endothelial cell proliferation |
| 01/29/2004 | US20040019052 5-(2,3-Difluorophenyl)-1H-pyrazolo(3,4-c)pyridazin-3-ylamine, e.g.; an enzyme inhibitor of GSK-3, a serine/threonine protein kinase; neuroprotectants in treatment of acute stroke, neurotraumatic injuries and diabetic conditions |
| 01/29/2004 | US20040019049 Substituted quinazolinone compounds |
| 01/29/2004 | US20040019048 Imidazo(4,5-c)quinoline and the 6,7,8,9-tetrahydro derivative having urea, thiourea, acylurea or sulfonylurea at the 1-position as immune response modifiers; biosynthesis of cytokines; viricides; antitumor, -carcinogenic agents |
| 01/29/2004 | US20040019046 Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
| 01/29/2004 | US20040019044 Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals |
| 01/29/2004 | US20040019040 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| 01/29/2004 | US20040019038 Compounds useful as anti-inflammatory agents |
| 01/29/2004 | US20040019037 E.g.,((5-(2,4-Diaminopyrimidin-6-yl)pentanoyl)-(N-methyl)amino )-3-(6-meth-oxypyridin-3-yl)-propanoic acid, inhibition of bone resorption, restenosis, angiogenesis inhibitors, antiarthritic, -tumor, -carcinogenic agents; antidiabetic |
| 01/29/2004 | US20040019035 3-(5,6,7,8-Tetrahydro-(1,8)naphthyridin-2-yl)-ethoxy)-11H-di-b enzo(1,4)oxazepin-10-yl)-acetic acid; inhibiting bone resorption; vascular restenosis; osteoporosis; angiogenesis inhibitors; diabetic retinopathy; anticarcinogenic agents |
| 01/29/2004 | US20040019034 Pyrrolotriazolopyrimidinone derivatives |
| 01/29/2004 | US20040019028 Administering to a patient with mild cognitive impairment, a specific glucocorticoid receptor antagonist such as mifepristone to improve performance on a paragraph recall test |
| 01/29/2004 | US20040019020 Phosphinyl phosphonate compounds treat hyperphosphatemia, chronic renal failure, disorders of phosphate metabolism, hyperparathyroidism, uremic bone disease, soft tissue calcification or osteoporosis |
| 01/29/2004 | US20040019018 Rigid pyrrolidone modulators of pkc |
| 01/29/2004 | US20040019016 Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor |
| 01/29/2004 | US20040019015 Administering an effective amount of a protein tyrosine kinase inhibitor (containing first and second module) to the patient to protect against or to treat hearing loss |
| 01/29/2004 | US20040019002 Gene repair involving the induction of double-stranded DNA cleavage at a chromosomal target site |
| 01/29/2004 | US20040019001 Modulation gene expression |
| 01/29/2004 | US20040018998 Antidiabetic agents; hypoglycemic agents; dietetics |
| 01/29/2004 | US20040018986 Viricide against hepatitis virus |
| 01/29/2004 | US20040018981 Glucagon-like peptide-1 (glp-1) receptor agonist |
| 01/29/2004 | US20040018980 Novel FIZZ proteins |
| 01/29/2004 | US20040018972 Autoimmune diseases; antiallergens; rheumatic diseases; antiinflammatory agents |
| 01/29/2004 | US20040018618 Genetic engineering; hybrid proteins; gene expression; human gene therapy |
| 01/29/2004 | US20040018558 Method for identifying modulators of G protein coupled receptor signaling |
| 01/29/2004 | US20040018542 Phosphodiesterase enzymes |
| 01/29/2004 | US20040018259 Use of at least one extract of a plant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 01/29/2004 | US20040018253 Administering a drug for which major clearance mechanism in humans is CYP2D6 mediated oxidative biotransformation in combination with a CYP2D6 inhibitor |
| 01/29/2004 | US20040018235 An anticholesterol agents comprising pitavastatin, for treating hypercholesterolemia; time-release agents |
| 01/29/2004 | US20040018190 Drugs and foods improving the quality of life and process for producing the same |
| 01/29/2004 | US20040018187 Attenuation of fibroblast proliferation |
| 01/29/2004 | DE10229778A1 Neue Verwendung von Imidazotriazinonen New use of imidazotriazinones |
| 01/29/2004 | DE10229379A1 EG-VEGF Rezeptor Antagonisten EG-VEGF receptor antagonists |
| 01/29/2004 | DE10229180A1 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen Use of vasopeptidase inhibitors for the treatment of metabolic disorders, nephropathy, and diseases associated with AGE |
| 01/29/2004 | CA2496912A1 Methods and compositions for treating diabetes mellitis |
| 01/29/2004 | CA2493876A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 01/29/2004 | CA2493774A1 2,4-dihydroxybenzoic acid derivatives |
| 01/29/2004 | CA2493721A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 01/29/2004 | CA2493339A1 2-cyano-4-fluoropyrrolidine derivative or salt thereof |
| 01/29/2004 | CA2493234A1 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| 01/29/2004 | CA2493230A1 5-substituted isoquinoline derivative |
| 01/29/2004 | CA2493202A1 Antitumor compound and therapeutic uses thereof |
| 01/29/2004 | CA2493000A1 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
| 01/29/2004 | CA2492941A1 Remedy |
| 01/29/2004 | CA2492922A1 Substituted thiophene carboxamide compounds for the treatment of inflammation |
| 01/29/2004 | CA2492906A1 Materials and methods for treating hypercholesterolemia |
| 01/29/2004 | CA2492878A1 Enhancing the effect of radioimmunotherapy in the treatment of tumors |
| 01/29/2004 | CA2492862A1 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 01/29/2004 | CA2492847A1 5-aryltetrazole compounds, compositions thereof, and uses therefor |
| 01/29/2004 | CA2492665A1 Azaindole kinase inhibitors |
| 01/29/2004 | CA2492651A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 |
| 01/29/2004 | CA2492498A1 Flea and tick octopamine receptor nucleic acid molecules, proteins and uses thereof |
| 01/29/2004 | CA2492331A1 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 01/29/2004 | CA2491251A1 1-heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| 01/29/2004 | CA2491248A1 1-heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 01/29/2004 | CA2491131A1 Novel compounds as histone deacetylase inhibitors |
| 01/29/2004 | CA2489982A1 Preparation of microbial oil containing polyunsaturated fatty acids |
| 01/29/2004 | CA2466288A1 Methods of treating conditions associated with an edg-1 receptor |
| 01/28/2004 | EP1384774A1 Glycosaminoglycan/collagen complexes and use thereof |
| 01/28/2004 | EP1384726A2 Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides |
| 01/28/2004 | EP1384488A2 Method and kit for imaging organs and tissues, using labelled antibodies |
| 01/28/2004 | EP1384477A1 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases |
| 01/28/2004 | EP1384081A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
| 01/28/2004 | EP1383927A2 New polynucleotides and polypeptides of the erythropoietin gene |
| 01/28/2004 | EP1383893A2 Proteins and nucleic acids encoding same |
| 01/28/2004 | EP1383892A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/28/2004 | EP1383890A2 Mutants of desoxycytidine kinase having extended enzymatic activity |
| 01/28/2004 | EP1383884A2 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| 01/28/2004 | EP1383872A2 Genetically modified yt cell line and use thereof |
| 01/28/2004 | EP1383793A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/28/2004 | EP1383786A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| 01/28/2004 | EP1383785A2 Recombinant tumor specific antibody and use thereof |
| 01/28/2004 | EP1383782A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 01/28/2004 | EP1383778A2 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 01/28/2004 | EP1383774A2 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/28/2004 | EP1383769A2 6-substituted pyrazolo 3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| 01/28/2004 | EP1383768A1 Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| 01/28/2004 | EP1383767A1 Trifluoromethylpurines as phosphodiesterase 4 inhibitors |
| 01/28/2004 | EP1383766A1 Disubstituted 1,7-guanines |
| 01/28/2004 | EP1383762A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same |
| 01/28/2004 | EP1383760A1 Biarylcarboxamide compounds as apolipoprotein b inhibitors |
| 01/28/2004 | EP1383759A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| 01/28/2004 | EP1383757A1 Antagonists of mcp-1 function and methods of use thereof |
| 01/28/2004 | EP1383753A1 Piperazine-benzamide derivatives useful as apob-100 and/or mtp inhibitor |
| 01/28/2004 | EP1383750A2 Urea derivatives as integrin alpha 4 antagonists |
| 01/28/2004 | EP1383748A2 Novel compounds and compositions as cathepsin inhibitors |
| 01/28/2004 | EP1383747A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| 01/28/2004 | EP1383746A2 New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 01/28/2004 | EP1383743A2 Dual inhibitors of pde 7 and pde 4 |
| 01/28/2004 | EP1383740A2 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
| 01/28/2004 | EP1383731A1 Biaryl compounds as serine protease inhibitors |
| 01/28/2004 | EP1383730A2 Anticholinergic compounds and methods of use |
| 01/28/2004 | EP1383729A1 Peptide deformylase inhibitors |
| 01/28/2004 | EP1383578A1 Single dose aromatase inhibitor for treating infertility |